DEM BioPharma Inc., a Cambridge, Mass.-based immuno-oncology startup, launched with a $70 million investment. Longwood Fund and Alta Partners led the round, which included participation from Insight Partners, Pfizer Ventures, Astellas Venture Management, Emerson Collective, UTokyo Innovation Platform and Alexandria Venture Investments. Jan Skvarka, former chief executive of Trillium Therapeutics, was named executive chairman.
MicroTransponder Inc., an Austin, Texas-based startup developing a neurostimulation device to improve hand and arm mobility in stroke survivors, closed a $53 million Series E round led by U.S. Venture Partners. New investors Osage University Partners, Action Potential Venture Capital and The Vertical Group also participated in the funding, along with existing backers Green Park & Golf Ventures and Exceller Hunt Ventures. In addition to the investment, MicroTransponder named Richard Foust as chief executive. He previously held positions at Velano Vascular, Analyte Health, Abbott Vascular, Guidant Corp. and Perclose. USVP’s Casey Tansey and Osage University Partners’ Bill Harrington will join the company’s board.
Therorna Inc., a China-headquartered developer of circular RNA technology-based vaccines and therapies, secured $42 million in Series A financing from investors including MSA Capital, Sherpa Healthcare Partners, 3H Health Investment, Quan Capital and Cenova Capital.
Carbon Biosciences, a Boston-based developer of novel parvovirus-derived gene therapies, raised $38 million in Series A funding. Agent Capital led the round, which included contributions from Longwood Fund, Astellas Venture Management, Cystic Fibrosis Foundation, Solasta Ventures, UTokyoIPC and Camford Capital. Additionally, Joel Schneider joined the company as president and chief executive. He was most recently chief operating officer at Solid Biosciences. Chen Schor, Adicet Bio president and CEO, was named board chair.
Elucid, a Boston-based developer of a non-invasive medical software for heart disease diagnosis, completed a $27 million Series B round from investors including Biovision Ventures, MedTex Ventures, IAG Capital Partners, Bold Brain Ventures and BlueStone Venture Partners.
Florence Healthcare, an Atlanta-based clinical trial software startup, landed $27 million in Series C1 funding led by Insight Partners.
AiVF, a Tel Aviv-based in vitro fertilization software platform, raised a $25 million Series A round led by Insight Partners.
Rivet, a Salt Lake City-based healthcare billing platform, collected $20.5 million in Series B funding. Catalyst Investors led the round, with Partner Tyler Newton joining the board. Additional investors included Ankona Capital, Menlo Ventures, Pelion Venture Partners and Lux Capital.
Gemelli Biotech Corp., a Raleigh, N.C.-based provider of precision diagnostics for gastrointestinal diseases, snagged $19 million in Series A funding. Lead investor Blue Ox Healthcare Partners was joined by Cedars-Sinai, Carolina Angel Network, CerraCap Ventures and others in the round.
Magnetic Insight Inc., an Alameda, Calif.-based imaging diagnostics startup, scored $17 million in Series B funding. Celesta Capital led the investment, which included contributions from Alumni Ventures Group, Gaingels, 5AM Ventures and Sand Hill Angels.
Idoven, a Madrid-based startup focused on early detection and precision medicine for cardiovascular diseases, nabbed $12.9 million in Series A financing. Insight Partners and Northzone led the round, with participation from Wayra. In addition to the Series A investment, Idoven picked up $6.9 million in grant and equity funding from the European Innovation Council Accelerator.
Vibe Biotechnology Inc., a Boston-based startup with a community-driven approach to identifying and developing treatments for rare diseases, picked up a $12 million investment. Led by Initialized Capital, the funding included additional support from 6th Man Ventures, Lerer Hippeau and others.
|